Jakafi, the only Incyte drug tracked here, made $3.1B of its 2025 revenue (60%) and loses US exclusivity in 2028. Since 2023, Incyte has closed 1 acquisition of $1B or more, worth $1.25B.
Bars are each drug's 2025 sales as a share of Incyte’s total revenue ($5.1B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Jul 2026 | Vega TherapeuticsIncyte 10-Q, Q2 2026 | $1.25B | Other | Latarcibart, a Phase 3 antibody for von Willebrand disease, a bleeding disorderA Star Therapeutics subsidiary; up to $0.75B more in sales milestones. | Pipeline only |
| 1 counted | $1.25B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Incyte announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Oncology | $3.1B | – |
| Other | – | $1.25B |
Incyte has the most revenue at risk in oncology, but has spent the most on acquisitions outside the main areas (Vega Therapeutics). At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Incyte paid, not the sales it will bring in. None of the companies it bought had an approved product at closing, so any sales from them are years away and may never arrive. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: Incyte 10-K 2025. Drug sales and dates are sourced on each drug's page; each deal links to Incyte’s announcement or filing in the table above.
See all 45 drugs on the patent cliff →